Browse by author
Lookup NU author(s): Simon Cotterill,
Professor Andrew Pearson
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In 1982 the European Neuroblastoma Study Group (ENSG) established a prospective registry for patients with newly diagnosed neuroblastoma ('The ENSG Survey'). Clinical information was collected primarily to: (a) establish an ENSG database; and (b) investigate prognostic factors in neuroblastoma. This paper summarises the results of the survey. By 1992, 1277 patients with a median age of 26 months (range: 0-289 months), gender ratio of 1.19 M:F had been registered from 30 centres. The median followup of survivors is 9.7 years (range: 1-14 years). Overall 5-year survival (S) is 45% (95% CI 42-48%), and event-free survival (EFS) is 43% (95% CI 40-45%). For both survival and EFS the key established prognostic factors, stage and age, are highly significant (P < 0.001). In particular, patients under 1 year of age at diagnosis, whatever the disease stage, had a more favourable prognosis than older patients; stage 2 (EFS 93% (95% (CI 85-97) versus 76% (95% CI 67-86), P = 0.02), stage 3 (EFS 91% (95% CI 82-96) versus 52% (95% CI 44-60), P < 0.001) and stage 4 (EFS 59% (95% CI 48-69) versus 16% (95% CI 13-19), P < 0.001). Multivariate analysis established that the anatomical location of the primary tumour (i.e. abdominal versus other sites) and primary tumour volume also conferred a statistically significant difference. In stage 4 disease the 20% of patients without demonstrable bone marrow involvement had a more favourable prognosis than those with infiltrated marrow (EFS 36% (95% CI 13-19) versus 16% (95% CI 29-45), P < 0.001). Urine catecholamine metabolite levels (raised versus normal), histology (ganglioneuroblastoma versus neuroblastoma) and gender had no significant effect on outcome after stage and age were accounted for. 5-year survival following first relapse is only 5.6% (95% CI 2.8-8.4). This ENSG Survey provides secure data for future comparisons with new prognostic factors and treatment programmes. (C) 2000 Elsevier Science Ltd. All rights reserved.
Author(s): Cotterill, S. J., Pearson, A. D. J., Pritchard, J., Foot, A. B. M., Roald, B., Kohler, J. A., Imeson, J.
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer
ISSN (print): 0959-8049
ISSN (electronic): 1879-0852
PubMed id: 10785596
Notes: Group Authors: European Neuroblastoma Study Group, UK Childrens Cancer Study Group UKC
Altmetrics provided by Altmetric